Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Oct;63(4):403-404.
doi: 10.1165/rcmb.2020-0243ED.

Bench to Bedside and Back: The Evolving Story of Alpha-1 Antitrypsin Deficiency

Kenneth R Chapman  1   2
Affiliations
Editorial

Bench to Bedside and Back: The Evolving Story of Alpha-1 Antitrypsin Deficiency

Kenneth R Chapman. Am J Respir Cell Mol Biol. 2020 Oct.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Laurell CB, Eriksson S. The electrophoretic alpha1-globullin pattern of serum in alpha1-antitrypsin deficiency. Scand J Clin Lab Invest. 1963;115:132–140.
    1. Wewers MD, Casolaro MA, Sellers SE, Swayze SC, McPhaul KM, Wittes JT, et al. Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema. N Engl J Med. 1987;316:1055–1062. - PubMed
    1. Vreim CE, Wu M, Crystal RG, Buist AS, Burrows B, Cohen AB, et al. Survival and FEV1 decline in individuals with severe deficiency of α1-antitrypsin. Am J Respir Crit Care Med. 1998;158:49–59. - PubMed
    1. Chapman KR, Stockley RA, Dawkins C, Wilkes MM, Navickis RJ. Augmentation therapy for alpha1 antitrypsin deficiency: a meta-analysis. COPD. 2009;6:177–184. - PubMed
    1. Chapman KR, Burdon JG, Piitulainen E, Sandhaus RA, Seersholm N, Stocks JM, et al. RAPID Trial Study Group. Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;386:360–368. - PubMed

Substances